Recruiting Alzheimers Disease Studies in Leuven
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors....
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
This pan-tumor trial is designed as a signal-seeking trial to assess efficacy and safety of raludotatug deruxtecan (R-DXd) monotherapy in locally advanced or metastatic solid tumors with various cadhe...
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
This is a Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses...
Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
Study J4B-MC-OKAA is a Phase 1/2, multi-center, open-label ascending dose, first-in-human study that will evaluate the safety and effect of intra-cisternal LY3884963 administration on progranulin prot...
About Alzheimers Disease Clinical Trials in Leuven
Alzheimer's disease is a progressive brain disorder that destroys memory, thinking skills, and the ability to carry out daily tasks. It is the most common cause of dementia, affecting over 6.7 million Americans age 65 and older. The disease is characterized by amyloid-beta plaques and tau tangles in the brain. Recent FDA approvals of anti-amyloid antibodies like lecanemab (Leqembi) and donanemab have opened a new era of disease-modifying treatments. Clinical trials are now exploring next-generation amyloid-clearing therapies, tau-targeting treatments, anti-inflammatory approaches, and combination strategies. Early-stage patients with mild cognitive impairment or early Alzheimer's are frequently sought for enrollment, and many trials now use blood-based biomarkers for screening.
There are currently 4 alzheimers disease clinical trials recruiting participants in Leuven, VLAAMS%20BRABANT. These studies are seeking a combined 806 participants. Research is being sponsored by Daiichi Sankyo, Denali Therapeutics Inc., Prevail Therapeutics. Clinical trial participation is free and participants receive study-related medical care at no cost.
Alzheimers Disease Clinical Trials in Leuven — FAQ
Are there alzheimers disease clinical trials in Leuven?
Yes, there are 4 alzheimers disease clinical trials currently recruiting in Leuven, VLAAMS%20BRABANT. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Leuven?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Leuven research site will contact you about next steps.
Are clinical trials in Leuven free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Leuven studies also compensate for your time and travel.
What alzheimers disease treatments are being tested?
The 4 active trials in Leuven are testing new therapies including novel drugs, biologics, and treatment approaches for alzheimers disease.
Data updated March 2, 2026 from ClinicalTrials.gov